By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting originating in Tokyo, Japan, by NewsRx journalists, research stated, "C-reactive protein (CRP) was an independent prognostic factor for metastatic renal cell carcinoma in the cytokine era. However, the impact of CRP on the survival of metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors has not yet been investigated."
The news reporters obtained a quote from the research from Cancer Institute Hospital, "Therefore, we further evaluated the prognostic impact of CRP for patients with metastatic renal cell carcinoma treated with molecular-targeted agents of tyrosine kinase inhibitors. Fifty-two patients were treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma at our institution. Overall, 31 and 21 patients were administered sunitinib and sorafenib, respectively. The prognostic value of all variables, including CRP, for overall survival was assessed using the Cox proportional hazards model. The median baseline CRP level was 4.9 mg/l. In multivariate analysis, CRP was an independent predictor for overall survival as both continuous and categorical variable. The median overall survival times of patients with non-elevated CRP concentration (
According to the news reporters, the research concluded: "CRP has a significant impact on overall survival of patients with metastatic renal cell carcinoma carcinoma treated with tyrosine kinase inhibitors."
For more information on this research see: Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. International Journal of Clinical Oncology, 2013;18(5):884-9. International Journal of Clinical Oncology can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA. (Springer - www.springer.com; International Journal of Clinical Oncology - www.springerlink.com/content/1341-9625/)
Our news correspondents report that additional information may be obtained by contacting Y. Yasuda, Dept. of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. Additional authors for this research include K. Saito, T. Yuasa, S. Kitsukawa, S. Urakami, S. Yamamoto, J. Yonese, S. Takahashi and I. Fukui (see also Biotechnology).
The publisher of the International Journal of Clinical Oncology can be contacted at: Springer, 233 Spring Street, New York, NY 10013, USA.
Keywords for this news article include: Asia, Biotechnology, Tokyo, Japan, Kidney, Albumins, Oncology, Carcinoma, Immunology, Nephrology, Proteomics, Immunoproteins, Tyrosine Kinase, C Reactive Protein, Cancer Gene Therapy, Acute Phase Proteins, Aromatic Amino Acids, Enzymes and Coenzymes.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC